Physician profile
Jason King
NPI 1871328039
$2,322.19
in general payments reported to CMS, 2019-2025
30 companies · $1,807 in 2025
The $1,807 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $515 · 2025: $1,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $323.19 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $216.98 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $189.92 | 2024-2025 | Enhertu, Datroway |
| Incyte Corporation | $142.55 | 2024-2025 | Jakafi |
| Glaxosmithkline, LLC. | $135.31 | 2025 | Ojjaara |
| Genentech USA, INC. | $115.93 | 2025 | Itovebi, Tecentriq, Venclexta |
| Janssen Biotech, INC. | $115.16 | 2024-2025 | Rybrevant |
| Caris Mpi, INC. | $106.73 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $106.60 | 2024-2025 | Ninlaro, Iclusig, Alunbrig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.76 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $102.93 | 2025 | Enhertu, Tagrisso |
| Lilly USA, LLC | $75.85 | 2024-2025 | Verzenio, Jaypirca |
| Pfizer INC. | $72.78 | 2025 | |
| Adaptive Biotechnologies Corporation | $53.58 | 2024-2025 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $51.05 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $45.57 | 2024-2025 | |
| Tersera Therapeutics LLC | $32.75 | 2024 | Zoladex |
| Pharmaessentia USA Corporation | $31.02 | 2025 | Besremi |
| Aveo Pharmaceuticals, INC. | $29.82 | 2025 | |
| Exelixis INC. | $29.71 | 2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $29.01 | 2024 | Ultomiris |
| Sobi, INC | $28.60 | 2025 | |
| Astellas Pharma US INC | $26.73 | 2025 | Vyloy |
| Ipsen Biopharmaceuticals, INC | $24.98 | 2025 | Onivyde |
| Array Biopharma INC | $24.60 | 2025 | Lorbrena, Braftovi, Tukysa |
| Jazz Pharmaceuticals INC. | $22.75 | 2025 | |
| Puma Biotechnology, INC. | $21.67 | 2025 | |
| Recordati_rare_diseases_inc. | $21.62 | 2025 | Sylvant |
| Beigene USA, INC. | $20.57 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $19.47 | 2025 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.